SPONSORED CONTENT
In fiscal year 2025, the Health Resources and Services Administration (HRSA) audited 115 covered entities — and 49% received adverse findings. In other words, nearly one in two programs had a 340B compliance issue last year.
While this is an improvement
…SPONSORED CONTENT
Q1 2026 started rougher than predicted for 340B programs. Ceiling prices compressed. Penny pricing disappeared on drugs that used to be your biggest savings. And an entire drug category that looked like a growth engine 12 months ago went dark almost
…
Q: Where did you grow up?
South Alabama
Q: Tell us about your educational background and training.
I graduated from Auburn University’s Harrison School of Pharmacy. My career as a pharmacist includes retail, hospital, and specialty pharmacy.
Q: What are your favorites?
Food: Mexican, chocolate
Movie: I do not watch many movies, but I
…
SPONSORED CONTENT
TIP: Regularly review your 340B ESP configuration to ensure alignment across TPA & wholesaler systems, because even small inconsistencies can quietly escalate into significant missed savings opportunities.
SPONSORED CONTENT
Uncertainty has become a constant in the 340B landscape. Legal challenges, shifting manufacturer policies, and evolving oversight have made one thing clear: waiting for definitive answers before taking action is no longer a viable strategy.
For covered entity leaders, the
Q: What is the primary problem RxParadigm’s Tungsten+PLUS™ solves?
Tungsten+PLUS™ is a transparent platform designed to eliminate 340B duplicate discounts, reconcile Inflation Reduction Act (IRA)-driven…
Read More »SPONSORED CONTENT
State-level oversight of the 340B Drug Pricing Program continues to expand. In 2025 alone, states including Colorado, Hawaii, Idaho, Indiana, Ohio, Rhode Island, and Vermont enacted laws requiring covered entities to report acquisition costs, reimbursement, and the use of 340B program savings.
…SPONSORED CONTENT
340B teams are facing ever-rising expectations and workloads. Programs must juggle core operational responsibilities while continuously adapting to evolving policies and regulatory changes (especially as we’ve experienced over the
…SPONSORED CONTENT
When the Health Resources and Services Administration (HRSA)’s 340B Rebate Model Pilot Program was put on temporary pause by a federal court in the waning days of 2025, most of the covered entity (CE) community celebrated the delay thinking they had avoided
…SPONSORED CONTENT
Join 340B Report’s Ted Slafsky for timely updates on 340B policy developments, including the latest on the 340B rebate pilot proposal, as well as key legal and legislative developments in the 340B arena. Then hear from Pillr Health’s Chief Pharmacy Officer,
…
